Advances in Obesity and Lipid Management in CVD for Cardiologists and Endocrinologists | A Textbook of Cardiology | Cutting Edge Multispeciality Strategies with GLP-1RAs, PCSK9i and Inclisiran: 1

Advances in Obesity and Lipid Management in CVD (Cutting Edge Strategies by Multispeciality Lens): A Textbook of Cardiology is the 14th focused textbook of cardiology published from India to the world, built specifically to map obesity and lipid management across every dimension of cardiovascular disease. Structured across 2 parts, 23 sections, and 172 chapters, it brings together more than 300 contributors from India and abroad, led by 14 Editors-in-Chief spanning cardiology, echocardiography, endocrinology, and nephrology. Part I covers Obesity Management: definitions and classification, the ACC/AHA and ESC guidelines, autoimmunity and genetics, cardiometabolic risk, and obesity's interaction with diagnostic markers, heart failure, coronary artery disease, hypertension, diabetes, cardiomyopathy, arrhythmia, cardiolipidology, aortic disease, stroke, kidney disease, and more. Part II covers Lipid Management in CVD, including dedicated Nonstatin Therapy and Future Directions sections. Each drug class gets its own focused treatment: GLP-1 receptor agonists (Semaglutide, Tirzepatide, Exenatide), SGLT2 inhibitors (Empagliflozin, Dapagliflozin), the nonsteroidal MRA Finerenone, and lipid-lowering agents spanning statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, inclisiran, lipoprotein apheresis, and gene therapy. Drug efficacy is assessed through biomarkers, echocardiography, and multimodality imaging throughout. Who This Book Is For: Cardiologists: get a single reference tying obesity and lipid pharmacology directly to CVD outcomes, from CAD and heart failure to arrhythmia and aortic disease. Endocrinologists: find dedicated chapters on obesity, diabetic dyslipidemia, and cardiometabolic risk written from a cardiovascular-outcomes lens. Diabetologists: get guideline-based coverage of GLP-1RA and SGLT2 inhibitor therapy for patients where diabetes, obesity, and CVD overlap. Nephrologists: find focused chapters on obesity's cardiorenal-metabolic continuum and SGLT2 inhibitor renoprotection in chronic kidney disease. Cardiology Postgraduates (DM/DNB): get exam-relevant, guideline-referenced chapters on the newest drug classes shaping current cardiology practice. Why This Book Helps: Connects obesity and lipid pharmacology to cardiovascular outcomes: instead of treating obesity, diabetes, and dyslipidemia as separate topics, each chapter frames them through their direct impact on CVD, CKD, and heart failure. Keeps you current on the newest drug classes: GLP-1 receptor agonists, SGLT2 inhibitors, PCSK9 inhibitors, and inclisiran are covered with trial data (including ORION and HPS-4) and practical prescribing guidance, not just mechanism. Applies international guidelines to Indian patients: ACC/AHA and ESC recommendations are reviewed specifically for what is applicable in Indian clinical practice. Extends beyond cardiology alone: chapters written from cardiac-anesthesia, nephrology, and critical-care perspectives give a genuinely multispecialty view of perioperative and ICU management in obese, dyslipidemic patients. Structures a fast-moving field into one reference: 172 chapters organized into 23 sections mean you can go straight to a specific drug class, comorbidity, or complication instead of searching multiple sources. Key Features: 172 chapters across 23 sections and 2 parts, from 300+ contributors in India and abroad Dedicated drug-class chapters on Semaglutide, Tirzepatide, Exenatide, Empagliflozin, Dapagliflozin, and Finerenone Full nonstatin lipid-lowering coverage: ezetimibe, bempedoic acid, PCSK9 inhibitors, inclisiran, apheresis, and gene therapy, including pooled ORION trial data Efficacy assessment through biomarkers, echocardiography, and multimodality imaging woven through every section Multispecialty lens spanning cardiology, endocrinology, nephrology, and critical care/cardiac anesthesia perspectives

Disclaimer:

• Advances in Obesity and Lipid Management in CVD for Cardiologists and Endocrinologists | A Textbook of Cardiology | Cutting Edge Multispeciality Strategies with GLP-1RAs, PCSK9i and Inclisiran: 1 book is not for reading online or for free download in PDF or eBook format.
• Table of Contents, Index, Syllabus, summary and image of Advances in Obesity and Lipid Management in CVD for Cardiologists and Endocrinologists | A Textbook of Cardiology | Cutting Edge Multispeciality Strategies with GLP-1RAs, PCSK9i and Inclisiran: 1 may be of a different edition or of the same title.
• Price can change due to reprinting, price change by publisher or sourcing cost change for imported books.